DPP-4 inhibitors: a patent review (2012 – 2014)

Bibliography

• Mentlein R, Heymann E, Scholz W, et al. Dipeptidyl peptidase IV as a new surface marker for a subpopulation of human T-lymphocytes. Cell Immunol 1984;89:11-19
   Google Scholar
• Yazbeck R, Sulda ML, Howarth GS, et al. Dipeptidyl peptidase expression during experimental colitis in mice. Inflamm Bowel Dis 2010;16:1340-51
   PubMed Web of Science ®Google Scholar
• Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 2009;58:641-51
   PubMed Web of Science ®Google Scholar
• Tian L, Gao J, Hao J, et al. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 2010;151:3049-60
   PubMed Web of Science ®Google Scholar
• Masur K, Schwartz F, Entschladen F, et al. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul Pept 2006;137:147-55
   PubMedGoogle Scholar
• Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and metaanalysis. Adv Ther 2012;29:14-25
   PubMed Web of Science ®Google Scholar
• Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012;14:561-7
   PubMedGoogle Scholar
• Tremblay AJ, Lamarche B, Deacon CF, et al. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:366-73
   PubMed Web of Science ®Google Scholar
• Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011;58:69-73
   PubMed Web of Science ®Google Scholar
• Gupta AK, Verma AK, Kailashiya J, et al. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets 2012;23:565-70
   PubMed Web of Science ®Google Scholar
• Chen L, Klein T, Leung PS. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med 2012;12:995-1004
   PubMed Web of Science ®Google Scholar
• Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011;60:1246-57
   PubMed Web of Science ®Google Scholar
• Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011;124:2338-49
   PubMed Web of Science ®Google Scholar
• Dobrian AD, Ma Q, Lindsay JW, et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 2011;300:E410-21
   Web of Science ®Google Scholar
• Bekur R, Nagaraja MV, Shivashankara KN, Stanley W. Sitagliptin-induced hemolysis. Indian J Pharmacol 2010;42:320-1
   Google Scholar
• Pitocco D, Zaccardi F, Martini F, et al. Severe leucopenia associated with sitagliptin use. Diabetes Res Clin Pract 2011;91:e30-2
   PubMed Web of Science ®Google Scholar
• Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. Hypertension 2009;54:468-70
   Google Scholar
• Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009;54:516-23
   PubMed Web of Science ®Google Scholar
• Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. Diabetes Care 2012;35:e60
   PubMedGoogle Scholar
• Yokota K, Igaki N. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Intern Med 2012;51:2041-4
   PubMed Web of Science ®Google Scholar
• Davidson JA. The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract 2013;19:1050-61
   PubMed Web of Science ®Google Scholar
• Bohannon N. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med 2009;121:40-5
   PubMed Web of Science ®Google Scholar
• Hopsu-Havu VK, Sarimo SS. Purification and characterization of an aminopeptidase hydrolysing glycyl-proline-naphthylamide. Hoppe Seylers Z Physiol Chem 1967;384:1540-50
   Google Scholar
• Liu Y, Hu Y, Liu T. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects. Curr Med Chem 2012;19:3982-99
   PubMed Web of Science ®Google Scholar
• Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25
   PubMedGoogle Scholar
• Patel BD, Ghate MD. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem 2014;74:574-605
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yang L, Zhou Z. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs. J Diabetes 2014;6:21-9
   Google Scholar
• Juillerat-Jeanneret L. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? J Med Chem 2014;57:2197-212
   PubMed Web of Science ®Google Scholar
• Mendieta L, Tarrago T, Giralt E. Recent patents of dipeptidyl peptidase IV inhibitors. Expert Opin Ther Pat 2011;21:1693-741
   PubMed Web of Science ®Google Scholar
• Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89
   PubMed Web of Science ®Google Scholar
• Matrix Laboratories. IN251197A1; 2012
   Google Scholar
• Matrix Laboratories. WO113634A1; 2007
   Google Scholar
• Orchid Chemicals & Pharmaceuticals. IN254994A1; 2013
   Google Scholar
• Li W, Yang C. US0184322A1; 2013
   Google Scholar
• DNJ Pharma. WO113750A1; 2014
   Google Scholar
• MSN Laboratories. WO111158A2; 2013
   Google Scholar
• Sanwa Kagaku Kenkyusho Co. JP056872A; 2013
   Google Scholar
• Sanwa Kagaku Kenkyusho Co. WO034626A1; 2014
   Google Scholar
• Sunshine Lake Pharma Co. WO000629A1; 2014
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. CN102453001A, 2012
   Google Scholar
• Institute of Materia Medica, Chinese Academy of Medical Sciences. CN103420981A; 2013
   Google Scholar
• Ningbo Institute of Technology, Zhejiang University. CN103333940A; 2013
   Google Scholar
• Chen S, Zhang Y. CN103483418A; 2013
   Google Scholar
• Okayama Prefecture. JP040111A; 2013
   Google Scholar
• Morinaga Milk Industry Co. JP184962A; 2013
   Google Scholar
• Nippi, Inc. WO065832A1; 2013
   Google Scholar
• Morinaga Milk Industry Co. WO133031A1; 2013
   Google Scholar
• Morinaga Milk Industry Co. WO133032A1; 2013
   Google Scholar
• Nippi, Inc. WO017474A1; 2014
   Google Scholar
• Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. CN102311448A; 2012
   Google Scholar
• KBP Biomedical Co. CN102863440A; 2013
   Google Scholar
• Aurobindo Pharma Ltd. WO076973A2; 2012
   Google Scholar
• Cadila Healthcare Ltd. WO147092A2; 2012
   Google Scholar
• Nanjing Huawei Pharmaceutical Science and Technology Development Co. CN103788070A; 2014
   Google Scholar
• Nanjing Huawei Pharmaceutical Science and Technology Development Co. CN103626775A; 2014
   Google Scholar
• Nanjing Huawei Pharmaceutical Science and Technology Development Co. CN103772323A; 2014
   Google Scholar
• UniTris Biopharma Co. CN103724352A; 2014
   Google Scholar
• LG Life Sciences Ltd. WO060590A2; 2012
   Google Scholar
• Shanghai Fochon Pharmaceutical Co. WO088680A1; 2012
   Google Scholar
• Shanghai Fochon Pharmaceutical Co. WO089123A1; 2012
   Google Scholar
• Cadila Healthcare Ltd. WO061031A1; 2014
   Google Scholar
• Merck Sharp & Dohme Corp. WO003250A1; 2013
   Google Scholar
• Merck Sharp & Dohme Corp. WO018355A1; 2014
   Google Scholar
• Merck Sharp & Dohme Corp. WO018350A1; 2014
   Google Scholar
• Merck Sharp & Dohme Corp. WO122920A1; 2013
   Google Scholar
• Shanghai Institute of Pharmaceutical Industry. CN103172635A; 2013
   Google Scholar
• Cadila Healthcare Ltd. IN2012MU03030A; 2014
   Google Scholar
• Jiangsu Chia-Tai Tianqing Pharmaceutical Co. CN103030631A; 2013
   Google Scholar
• Shanghai Fochon Pharmaceutical Co. WO089122A1; 2012
   Google Scholar
• Shanghai Fochon Pharmaceutical Co. WO088677A1; 2012
   Google Scholar
• Prosidion Ltd. GB2497351A; 2013
   Google Scholar
• Merck Sharp & Dohme Corp. WO006526A2; 2013
   Google Scholar
• Schering Corp. WO078448A1; 2012
   Google Scholar
• Advinus Therapeutics Private Ltd. IN2008CH00746A; 2012
   Google Scholar
• Divi’s Laboratories Ltd. INCH02189A; 2013
   Google Scholar
• 2Y-Chem, Ltd. WO059938A1; 2014
   Google Scholar
• Chengdu Diao Pharmaceutical Group Co. CN103172633A; 2013
   Google Scholar
• Shanghai Institute of Pharmaceutical Industry. CN103254193A; 2013
   Google Scholar
• Shanghai Institute of Pharmaceutical Industry. CN103373999A; 2013
   Google Scholar
• Chengdu Easton Pharmaceutical Co. CN103509022A; 2014
   Google Scholar
• Chengdu Easton Pharmaceutical Co. CN103509023A; 2014
   Google Scholar
• Chengdu Easton Pharmaceutical Co. CN103936738A; 2014
   Google Scholar
• Shanghai Sun-Sail Pharmaceutical Science & Technology Co. CN103848835A; 2014
   Google Scholar
• Shanghai Fochon Pharmaceutical Co. WO089127A1; 2012
   Google Scholar
• Advinus Therapeutics Private Ltd. IN2009CH02720A; 2012
   Google Scholar
• Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences. CN103044391A; 2013
   Google Scholar
• Lianyungang Runzhong Pharmaceutical Co. CN103044392A; 2013
   Google Scholar
• Boehringer Ingelheim International GmbH. WO010964A1; 2013
   Google Scholar
• Shandong Luoxin Pharmacy Stock Co. CN103172615A; 2013
   Google Scholar
• Shandong Luoxin Pharmacy Stock Co. CN103193762A; 2013
   Google Scholar
• China Pharmaceutical University. CN103664893A; 2014
   Google Scholar
• Qilu Pharmaceutical Co. CN103848811A; 2014
   Google Scholar
• Martín M, Huguet J, Centelles JJ, Franco R. Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J Immunol 1995;155:4630-43
   PubMedGoogle Scholar
• Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 1998;16:27-42
   Google Scholar
• De Meester I, Korom S, Van Damme J, Scharpé S. CD26, let it cut or cut it down. Immunol Today 1999;20:367-75
   PubMedGoogle Scholar
• Struyf S, Proost P, Schols D, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999;162:4903-9
   PubMed Web of Science ®Google Scholar
• Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-51
   PubMed Web of Science ®Google Scholar
• Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:5025-37
   PubMed Web of Science ®Google Scholar
• Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297-300
   PubMed Web of Science ®Google Scholar
• Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007;50:6450-3
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 2005;7:253-69
   PubMed Web of Science ®Google Scholar
• Ospelt C, Mertens JC, Jüngel A. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2010;62:1224-35
   PubMedGoogle Scholar
• Gotoh H, Hagihara M, Nagatsu T, et al. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Chem 1989;35:1016-18
   PubMedGoogle Scholar
• Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010;88:125-31
   PubMed Web of Science ®Google Scholar
• Garg MK, Kharb S, Pandit A. Prescribing gliptins: enthusiasm should be coupled with caution. Indian J Endocrinol Metab 2012;16:324-5
   PubMedGoogle Scholar
• Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011;13:302-12
   PubMed Web of Science ®Google Scholar
• D’Amico M, Di Filippo C, Marfella R, et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice. Exp Gerontol 2010;45:202-7
   PubMed Web of Science ®Google Scholar
• Novartis Ag. US0017015A1; 2009
   Google Scholar
• Probiodrug Ag. US8168199B2; 2008
   Google Scholar
• Signpath Pharma. US0237590A1; 2012
   Google Scholar
• Signpath Pharma. WO125830A2; 2012
   Google Scholar
• Japan Tobacco Inc. WO049566A1; 2012
   Google Scholar
• Albireo AB. WO064267A1; 2012
   Google Scholar
• BioKier. WO151252A2; 2012
   Google Scholar
• Alla Chem. WO161622A2; 2012
   Google Scholar
• Translational Genomics Research Institute. WO171015A2; 2012
   Google Scholar
• Merck Sharp & Dohme. WO173877A1; 2012
   Google Scholar
• Jilin University. CN102793711A; 2013
   Google Scholar
• Ausa Pharmed Co. CN103417971A; 2013
   Google Scholar
• OAO "Khimiko-Farmatsevticheskii Kombinat Akrikhin". RU2485952C2; 2013
   Google Scholar
• Boehringer Ingelheim International GmbH. WO174769A1; 2013
   Google Scholar
• IPCA Laboratories Ltd. WO054345A2; 2013
   Google Scholar
• IPCA Laboratories Ltd. US0128402A1; 2014
   Google Scholar
• Boehringer Ingelheim International GmbH. WO098372A1; 2013
   Google Scholar
• Boehringer Ingelheim International GmbH. WO131967A1; 2013
   Google Scholar
• Boehringer Ingelheim International GmbH. WO174768A1; 2013
   Google Scholar
• Boehringer Ingelheim International GmbH. WO174767A1; 2013
   Google Scholar
• TransTech Pharma. WO173417A2; 2013
   Google Scholar
• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. CN103394089A; 2013
   Google Scholar
• Boehringer Ingelheim International GmbH. US0303462A1; 2013
   Google Scholar
• The Affiliated Hospital of Medical College Qingdao University. CN103566358A; 2014
   Google Scholar
• China Pharmaceutical University. CN103933031A; 2014
   Google Scholar
• Sanwa Kagaku Kenkyusho Co. JP080418A; 2014
   Google Scholar
• Ranbaxy Laboratories Ltd. WO080383A1; 2014
   Google Scholar
• Ranbaxy Laboratories Ltd. WO102715A1; 2014
   Google Scholar
• Siegfried International AG. WO128209A1; 2014
   Google Scholar
• National University Corporation Tokyo Medical and Dental University. WO064811A1; 2014
   Google Scholar